Global review of multidrug therapy (MDT) in leprosy

S K Noordeen1, L Lopez Bravo, D Daumerie

  • 1Leprosy Unit, World Health Organization, Geneva.

World Health Statistics Quarterly. Rapport Trimestriel De Statistiques Sanitaires Mondiales
|January 1, 1991
PubMed

Insights

Multidrug therapy (MDT) has significantly reduced leprosy cases by over 30% globally since 1985. High treatment compliance and widespread MDT coverage offer bright prospects for further leprosy prevalence reduction.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Tropical Medicine

Background:

  • Leprosy remains a significant global public health issue, particularly in Asia, Africa, and Latin America.
  • Historically, leprosy case numbers increased until 1985, posing a substantial disease burden.

Purpose of the Study:

  • To evaluate the impact of multidrug therapy (MDT) on global leprosy prevalence.
  • To assess the current status and future prospects of leprosy control programs.

Main Methods:

  • Analysis of registered leprosy case data from 1966 to 1990.
  • Review of multidrug therapy (MDT) coverage and patient treatment completion rates.
  • Assessment of treatment compliance and tolerability of MDT.

Main Results:

  • A reduction of over 30% in registered leprosy cases since 1985, attributed to MDT.
  • Global MDT coverage reached 55.7% by October 1990, with over 2 million patients undergoing treatment and 1 million completing it.
  • MDT demonstrated good tolerability and high acceptability, leading to improved patient compliance.

Conclusions:

  • MDT has been highly effective in reducing leprosy prevalence, with strong prospects for further decreases.
  • Challenges remain in early case detection and managing long-term disabilities in leprosy patients.
  • Addressing regional variations in MDT coverage is crucial for global leprosy control efforts.

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...